$100B+ Market Target for Sub-Penny Play IMMB; HIV/AIDS,
Hepatitis C, Cancer Treatments in the Works
Hi and good afternoon,
Tonight we are looking at a play with an extremely
low float (only 9Mln) that is currently sitting at just 0045. I dont know if weve ever
covered anything like this before, so lets get to it:
taken the nation and world by storm over the last month or two.
Turn on you TV; its what is being talked about. Liberal
channels, conservative channels
it doesnt matter.
Its the hottest topic of them all.
And why not? Ebola
is terrifying. Im sure by now youve taken
the time to read or watch one of those Get the Facts about
Ebola webpages: 80pct mortality rate, if treatment methods
dont change cases could reach 1.4Mln by January of next
year, the current Ebola epidemic is 14 times larger than the
bigger than the last largest outbreak, over 54pct of health care
workers that became infected have died despite having full access
As I said, its frightening to think about.
This new Ebola scare has translated into a birth of monumental
breakouts for many biotech companies
a virtual overnight
and its still going on:
Generex went from .0161 to .0388, a run of
Aethlon went from .1025 to .3070, a run of over
Ibio went from .24 to 3.48, a run of 1350pct
Alpha Pro Tech went from 2.03 to 10.73, a run of over
Tekmira went from 8.86 to 29.93, a run of over 237pct
The list goes on. Some smaller biotech companies saw short-term
jumps in the multiple thousands of percent.
Tonight were profiling a small biotech company that has
already reached some impressive milestones and has extensive
experiments in viral treatments and other immuno related
disorders. In fact, when you see the numbers on this company you
may feel the same immediate excitement that I felt the first time
I saw them:
The low float (as stated
by otcmarkets . com)
Its current level of
only 0045 (less than half a cent)
The multitude of
immune-therapeutic treatments (one of which has
successfully completed Phase I and Phase II field trials)
These are the type of numbers that I love to see (but rarely do)
and with such low levels even just a slight increase in activity
could lead to some out-of-this-world percentage increases.
This drug development company is working on solving some of the
biggest medical issues of our time
in particular HIV/AIDS,
Cancer and other immuno related disorders.
Immunotech is a drug development company committed to the
commercialization of its proprietary proteins for the treatment
of debilitating infectious diseases. The Company strives to
become a leader in immune-therapeutic treatment and prevention of
HIV/AIDS, Cancer and other immune related disorders.
Company is the Real Deal, in case you havent
seen their recent news; IMMB recently announced the successful
completion of Phase I and Phase II field trials in Bulgaria of
the Companys HIV/AIDS and Hepatitis C virus treatment
(ITV-1 Treatment) and has begun negotiations for sites in
Macedonia and Serbia for Phase III testing on human patients.
Take a look at the following excerpt for the most recent company
The successful completion of Phase III clinical study
testing would enable Immunotech Laboratories (IMMB) to move
forward using the Phase I, II, & III clinical trial results,
for the FDA application pertaining to legal use of the treatment
for HIV/AIDS and Hepatitis C patients in the
Immunotechs flagship compound is ITV-1 (Immune
Therapeutic Vaccine-1). ITV-1 is a suspension of
Inactivated Pepsin Fraction (IPF), which studies have shown
is effective in the treatment of HIV/AIDS.
IPF has already shown great promise in treating HIV infections
while overcoming the cost, toxicity, compliance and drug
resistance of existing treatments. The results of four non-US
experimental trials on 200 patients
show the action and effectiveness of the vaccine.
Immunological results are:
Increase in percentages and numbers of CD8
and CCR5 positive cells in the treated patients.
Significant increase in CD8+, CD38+ cells in the
Significant increase in both CD4+ iNFg, secreting
cells in the treated patients.
While ITV -1 is IMMBs flagship compound for the treatment
of HIV/AIDS, the Company also has other compounds in their
pipeline which extends to Prenatal and Pediatric HIV, as well as
the development of an HIV vaccine.
IPF has also demonstrated advantages over traditional HIV
Significantly fewer and milder side
Does not cause viral mutation
Requires only a short treatment cycle
Enhances the immune system and enhances quality of
Simple and short treatment modality without
Treatment of drug resistant patients
In addition to treating HIV/AIDS patients with IPF, it has also
been found useful for detecting and
treating numerous types of cancer and hepatitis.
Company recently announced that they have entered negotiations to
pursue the development of market opportunities and Clinical
Testing for the Companys HIV/AIDS and Hepatitis C virus
treatment in Africa. There are an estimated 30M people in
Africa alone who suffer from HIV/AIDS.
Now while thats half a world away for many of us, viral and
immune disorders are also an ever-present staple in our society
as well. Just look at the uprising over Ebola.
What does that mean? You ask. How does that translate into market
share, size, etc? The numbers are staggering:
The global market for HIV therapeutics and
diagnostics is expected to grow to 18.2Bln in 2013.
Analysts forecast the Global HIV/AIDS Testing market
will grow at a CAGR of 5.4% to 2018.
Research from Datamonitor Healthcare has revealed
that the Hepatitis C market is forecast to grow to 230%.
GMR Data forecasts that the global cancer treatment
market will reach 143.7B by 2023.
The market for cancer immunotherapy in major world
markets is projected to grow to nearly 9Bln by 2022.
In 2010, the global market for drugs for the
treatment of immune disease was estimated at approximately
At just 0045 even a slight move
could translate to massive percentages.
IMMB seems to be the real deal and has a LOT going
for them at the moment.
Considering the current Ebola driven environment and the recent
biotech rush IMMB could be finding itself in the right place at
the right time; so get started on researching this exciting
biotech company right away.
Remember, we always encourage you to do further research. Never
take our word for it, read our disclaimer to see why, and of
course always consult a professional.
Just because a situation looks great things can still go wrong
and often do. Be smart and protect yourself.
Enjoy your afternoon,